<DOC>
	<DOCNO>NCT01417494</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , leucovorin calcium , fluorouracil , irinotecan hydrochloride , oxaliplatin , work different way stop growth tumor cell , either kill cell stop dividing . Monoclonal antibody , bevacizumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Giving bevacizumab together combination chemotherapy may better way block tumor growth . It yet know whether combination chemotherapy effective give together without bevacizumab treat patient colorectal cancer . PURPOSE : This randomized phase II trial study side effect give bevacizumab together first-line chemotherapy see well work treat old patient metastatic colorectal cancer .</brief_summary>
	<brief_title>1st Line Chemotherapy Alone With Bevacizumab Treating Older Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To evaluate composite efficacy safety , term objective response tumoral stability RECIST criterion deterioration Spitzer QoL Index score ≥ 2 point 4 month , old patient unresectable metastatic colorectal adenocarcinoma treat bevacizumab first-line chemotherapy . - To evaluate tolerance , term grade 4 arterial hypertension , grade 3-4 thromboembolic event , grade 3-4 cardiac insufficiency , hospitalization link chemotherapy , patient . Secondary - To evaluate toxicity patient . - To assess time deterioration autonomy patient . - To assess survival deterioration autonomy patient . - To evaluate time deterioration quality life patient . - To evaluate percentage patient receive least 2/3 protocol treatment month 4 . - To assess time treatment failure patient . - To assess progression-free survival global survival patient . Tertiary - To test predictive factor treatment success identify geriatric evaluation , accord main judgment criterion , analysis evolution geriatric parameter follow-up int patient . ( Exploratory ) OUTLINE : This multicenter study . Patients stratify accord chemotherapy ( monotherapy v double chemotherapy ) , primary tumor ( resect vs non-resected ) , quality-of-life score evaluate Spitzer QoL Index ( 0-3 v 4-7 vs 8-10 ) . Patients randomize 1 2 treatment arm . - Arm A : Patients receive 1 follow regimen accord discretion investigator : - Simplified LV5FU2 comprise leucovorin calcium IV 2 hour day 1 15 fluorouracil IV 46 hour begin day 1 15 . - FOLFIRI comprise leucovorin calcium IV 2 hour day 1 15 ; irinotecan hydrochloride IV 2 hour day 1 15 ; fluorouracil IV 46 hour begin day 1 15 . - FOLFOX4 comprise oxaliplatin IV 2 hour day 1 15 ; leucovorin calcium IV 2 hour day 1 15 ; fluorouracil IV 46 hour begin day 1 15 . All treatment regimens repeat every 4 week least 6 month absence disease progression unacceptable toxicity . - Arm B : Patients receive chemotherapy arm A . Patients also receive bevacizumab IV 90 minute day 1 15 . Treatment repeat every 4 week least 6 month absence disease progression unacceptable toxicity . Quality life assess periodically . Blood specimen collect evaluation quantification circulate cell early prediction response treatment . After completion study therapy , patient follow every 2-3 month .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic colorectal adenocarcinoma Unresectable disease Measurable disease RECIST criteria No cerebral metastasis PATIENT CHARACTERISTICS : ECOG performance status 02 Life expectancy ≥ 3 month Polynuclear neutrophils &gt; 1,500/mm^3 Platelet count &gt; 100,000/mm^3 Proteinuria ≤ 1 g 24hour urine collection No unresolved intestinal occlusion subocclusion No progressive unstabilized malignant tumor within past 2 year No progressive gastroduodenal ulcer , wound , bone fracture No active cardiac disease include follow : Hypertension adequately control Myocardial infarction within past 6 month Poorly control angina Decompensated congestive cardiac insufficiency No history arterial thromboembolism follow within past 12 month : Cerebrovascular accident Transient ischemic attack Subarachnoid hemorrhage No history distal visceral ischemic arterial pathology ≥ grade 2 within past 12 month No history lifethreatening pulmonary embolism within past 6 month Must complete geriatric selfadministered questionnaire geriatric `` team '' questionnaire ( include Spitzer QoL Index ) PRIOR CONCURRENT THERAPY : No prior chemotherapy metastatic disease More 6 month since adjuvant chemotherapy resection primary tumor More 4 week since major surgery , exclude biopsy More 4 week since radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>75 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>stage IVA colon cancer</keyword>
	<keyword>stage IVB colon cancer</keyword>
	<keyword>adenocarcinoma rectum</keyword>
	<keyword>stage IVA rectal cancer</keyword>
	<keyword>stage IVB rectal cancer</keyword>
</DOC>